Relugolix clinical trials
Also written TAK-385, Orgovyx and MVT-601.
How each study uses relugolix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the relugolix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Dec 2020 · ORGOVYX · NDA 214621 (FDA, Drugs@FDA)
- European Union
- 16 Jul 2021 · Ryeqo · EMEA/H/C/005267 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 11 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 18
Myovant Sciences GmbH (10) · Takeda (9) · Millennium Pharmaceuticals, Inc. (3) · NRG Oncology (2) · Emory University (2) · Sumitomo Pharma Switzerland GmbH (2) · AdventHealth (1) · Atish Choudhury, MD (1)
Often tested with
Tested in the same studies.
Leuprolide (5) · Darolutamide (3) · Bicalutamide (2) · Degarelix (2) · Triptorelin (2) · Estradiol (2) · Enzalutamide (2) · Buserelin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test relugolix, phase 3 first.
- Nov 2026Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPhase 3 · NRG Oncology
- Nov 2026Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsPhase 3 · Qilu Pharmaceutical Co., Ltd.
- Jul 2027RecoverPC: Relugolix vs GnRH Agonist in Quality of LifePhase 2 · Dana-Farber Cancer Institute
Studies
Open first, then newest update. How each study uses relugolix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 45
- Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate CancerRecruitingPhase 2University of UtahNCT07216248Written as relugolix + ARPI
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingPhase 2Sean SachdevNCT06499870Written as Relugolix
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA TrialRecruitingPhase 2Mayo ClinicNCT07025369Written as Relugolix
- The SUGAR Study; SBRT and Relugolix) for Prostate CancerRecruitingPhase 2Yale UniversityNCT06111781Written as Relugolix 120 MG [Orgovyx]
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingPhase 2Baptist Health South FloridaNCT07455903Written as Relugolix
- RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeRecruitingPhase 2Dana-Farber Cancer InstituteNCT05765500Written as Relugolix
- The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled TrialRecruitingPhase 3Main Line HealthNCT06439524Written as 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate CancerRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT06330805Written as Relugolix
- Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingPhase 1University of OklahomaNCT06130995Written as Relugolix and Enzalutamide
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingPhase 3Emory UniversityNCT06650579Written as Relugolix
- Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06671548Written as Relugolix
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisRecruitingPhase 3Sumitomo Pharma Switzerland GmbHNCT05862272Written as Relugolix Combination Tablet
- Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate CancerNot yet recruitingPhase 2University of Kansas Medical CenterNCT06129851Written as Relugolix
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerActive, not recruitingPhase 1AdventHealthNCT06631521Written as Relugolix
- Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyActive, not recruitingPhase 2NRG OncologyNCT05053152Written as Relugolix
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Relugolix
- Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateCompletedPhase 3Sumitomo Pharma America, Inc.NCT05605964Written as Relugolix
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for PregnancyCompletedPhase 3Sumitomo Pharma Switzerland GmbHNCT04756037Written as Relugolix Combination Therapy
- Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)Active, not recruitingPhase 2Atish Choudhury, MDNCT06463457Written as Relugolix
- RElugolix VErsus LeUprolide Cardiac TrialActive, not recruitingPhase 2Emory UniversityNCT05320406Written as Relugolix
See all 45 studies that test relugolix →
Given beside what is tested · 5 — relugolix is usual care or a partner of the new treatment
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as Relugolix
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Degarelix & Relugolix
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as Relugolix
- A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesCompletedPhase 2Janssen Research & Development, LLCNCT04523207Written as Relugolix
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT04666129Written as Relugolix
As the comparator · 2 — what is tested is compared with relugolix
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Relugolix
- Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17Not yet recruitingPhase 1/2University of WashingtonNCT06312761Written as Relugolix 120Mg Tab
Codes
What other systems call relugolix · ClinicalTrials.gg INT005900
- MeSH (NLM) C561634relugolixOne source ClinicalTrials.gov
- UNII (FDA) P76B05O5V6RELUGOLIXConfirmed FDA, Wikidata
- RxNorm 2472778One source FDA
- Wikidata Q21099000relugolixConfirmed FDA, Wikidata
- NCI Thesaurus C114498RelugolixOne source FDA
- DrugBank DB11853One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561634 | relugolix | One source ClinicalTrials.gov |
| UNII (FDA) | P76B05O5V6 | RELUGOLIX | Confirmed FDA, Wikidata |
| RxNorm | 2472778 | — | One source FDA |
| Wikidata | Q21099000 | relugolix | Confirmed FDA, Wikidata |
| NCI Thesaurus | C114498 | Relugolix | One source FDA |
| DrugBank | DB11853 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.